
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics Inc. is demonstrating strong momentum in its Filspari product, evidenced by a robust increase in new patient starts, which rose 37% quarter-over-quarter in 4Q24. The anticipated regulatory updates and potential expansion into focal segmental glomerulosclerosis (FSGS) signify a substantial market opportunity, projected to reach approximately $521 million by 2030. With the company planning to file a supplemental new drug application for Filspari and improving its probability of success in FSGS significantly, there is a promising outlook for continued growth and revenue enhancement.
Bears say
The analysis highlights significant commercial risks for Travere Therapeutics, particularly regarding its therapy Filspari, which may not achieve consensus estimates for the indications IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Furthermore, 70% of IgAN patients are below the key growth driver metric of 1.5 g/g, indicating a limited patient population that could directly benefit from Filspari. The competitive landscape poses additional challenges, with rival therapies potentially offering superior efficacy or safety profiles, alongside the looming threat of earlier generic competition impacting future revenue forecasts.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares